A neoantigenic determinant in coiled coil region of human fibrin β-chain

Thrombosis Research

Volumn 123, Issue 5, 2009, Pages 765-770

  Lugovskoy, E V ^a   Gritsenko, P G ^a   Kolesnikova, I N ^a   Lugovskaya, N E ^a   Komisarenko, S V ^a  

^a PALLADIN INSTITUTE OF BIOCHEMISTRY   (Ukraine)

Author keywords

Fibrin; Monoclonal antibody; Neoantigenic determinant

Indexed keywords

EPITOPE; FIBRIN BETA CHAIN; FIBRIN DERIVATIVE; FIBRIN DESAA; FIBRIN DESAABB; FIBRIN PROTOFIBRIL; FIBRINOGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FNL 3C; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN POLYMERIZATION; HUMAN; IMMUNOBLOTTING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; TRANSMISSION ELECTRON MICROSCOPY;

ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FIBRIN; HUMANS;

EID: 60449088708     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.08.024     Document Type: Article

References (42)

1. Blomback B. Fibrinogen and fibrin - proteins with complex roles in haemostasis and thrombosis. Thromb Res 83 (1996) 1-75
2. Yang Z., Kollman J.K., Pandi L., and Doolittle R.F. Crystal structure of native chicken fibrinogen at 2.7 Å resolution. Biochemistry 40 (2001) 12515-12523
3. Brown J., Volkmann N., Jun G., Henschen-Edman A.H., and Cohen C. The crystal structure of modified bovine fibrinogen. Proc Natl Acad Sci USA 97 (2000) 85-90
4. Burton R.A., Tsurupa G., Hantgan R.R., Tjandra N., and Medved L. NMR solution structure, stability, and interaction of the recombinant bovine fibrinogen alphaC-domain fragment. Biochemistry 46 (2007) 8550-8560
5. Shainoff J.R., Smejkal G.B., DiBello P.M., Mitkevich O.V., Levy P.J., Dempfle C.E., et al. Isolation and characterization of the fibrin intermediate arising from cleavage of one fibrinopeptide A from fibrinogen. J Biol Chem 271 (1996) 24129-24137
6. Weisel J.W., Veklich Y., and Gorkun O. The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral agregation in fibrin clots. J Mol Biol 232 (1993) 285-297
7. Weisel J.W. Fibrin assembly. Lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J 50 (1986) 1079-1093
8. Siebenist K.R., Di Orio J.P., Budzynski A.Z., and Mosesson. The polymerization and thrombin-binding properties of des-(Bβ1-42)-fibrin. J Biol Chem 265 (1990) 18650-18655
9. Moskowitz K.A., and Budzynski. The (DD)E complex is maintained by a composite fibrin polymerization site. Biochemistry 33 (1994) 12937-12944
10. Lugovskoy E.V., Gritsenko P.G., Kapustianenko L.G., Kolesnikova I.N., Chernishov V.I., and Komisarenko S.V. Functional role of Bbeta-chain N-terminal fragment in the fibrin polymerization process. FEBS J 274 (2007) 4540-4549
11. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 936 (2001) 291-4511
12. Medved L., and Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 89 (2003) 409-419
13. Gaffney P.J. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann N Y Acad Sci 936 (2001) 594-610
14. Olexa S.A., Budzynski A.Z., Doolittle R.F., Cottrell B.A., and Greene T.C. Structure of fragment E species from human cross-linked fibrin. Biochemistry 20 (1981) 6139-6145
15. Collen D., Kudryk B., Hessel B., and Blomback B. Primary structure of human fibrinogen and fibrin. Isolation and partial characterization of chains of fragment D. J Biol Chem 250 (1975) 5808-5817
16. Lugovskoi E.V., and Komisarenko S.V. The use of monoclonal antibodies for studying the fibrin polymerization. Russ J Bioorganic Chem 26 (2000) 791-798
17. Dempfle C.E. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 82 (1999) 673-683
18. Varetskaya T.V. Microheterogeneity of fibrinogen. Cryofibrinogen. Ukr Biokhim Zhurn 32 (1960) 13-24
19. Belitser V.A., Varetskaja T.V., and Malneva. Fibrinogen-fibrin interaction. Biochim Biophys Acta 154 (1968) 376
20. Lugovskoi E.V., and Gogolinskaya G.R. Preparation of fibrin desAA by thrombin. Ukr Biokhim Zhurn 71 (1999) 107-108
21. Timpl R., and Gollwitzer. Cyanogen bromide cleavage of bovine fibrinogen. Identification of a dimeric N-terminal peptide and two other disulfide containing fragments. FEBS Lett 29 (1973) 92-96
22. Nieuwenhuizen W., and Gravesen M. Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen, produced by plasmin (fragments X). Biochim Biophys Acta 668 (1981) 81-88
23. Marder V.J., Budzynski A.Z., and Barlow G.H. Comparison of the physiochemical properties of fragment D derivatives of fibrinogen and fragment DD of cross-linked fibrin. Biochim Biophys Acta 427 (1976) 1-14
24. Köhler G., and Milstein. Continuous cultures of fused cells secreting antibody of predefined specifity. Nature 256 (1975) 495-497
25. Friquet B., Alain F., Chaffte F., Djavadi-Ohaniance L., and Goldberg. Measurement of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77 (1985) 305-319
26. Lugovskoi E.V., Makogonenko E.M., Chudnovets V.S., Derzskaya S.G., Gogolinsikaja G.K., Kolesnikova I.N., et al. The study of fibrin polymerization with monoclonal antibodies. Biomed Sci 2 (1991) 249-296
27. Lugovskoy E.V., Gritsenko P.G., Kolesnikova IN Zolotareva E.N., Chernishov V.I., Nieuwenhuizen W., and Komisarenko S.V. Two monoclonal antibodies to D-dimer - specific inhibitors of fibrin polymerization. Thromb Res 113 (2004) 251-259
28. Weisel J.W., and Medved L. The structure and function of the alpha C domains of fibrinogen. Ann N Y Acad Sci 936 (2001) 312-327
29. Litvinov R.I., Yakovlev S., Tsurupa G., Gorkun O.V., Medved L., and Weisel J.W. Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other. Biochemistry 46 (2007) 9133-9142
30. Dempfle C.E., Dollman M., Lill H., Puzzovio D., Dessauer A., and Heene D.L. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN. Blood Coagul Fibrinolysis 4 (1993) 79-86
31. Hamano A., Tanaka S., Takeda Y., Umeda M., and Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta 318 (2002) 25-32
32. Hui K.Y., Haber E., and Matsueda G.R. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 222 (1983) 1129-1132
33. Soe G., Kohno I., Inuzuka K., Itoh Y., and Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma. Blood 88 (1996) 2109-2117
34. Schielen W.J., Voskuilen M., Tesser G.I., and Nieuwenhuizen W. The sequence A alpha-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies. Proc Natl Acad Sci USA 86 (1989) 8951-8954
35. Suzuki A., Ebinuma H., Matsuo M., Miyazaki O., and Yago H. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. Thromb Res 121 (2007) 377-385
36. Schielen W.J., Adams H.P., van Leuven K., Voskuilen M., Tesser G.I., and Nieuwenhuizen W. The sequence gamma-(312-324) is a fibrin-specific epitope. Blood 77 (1991) 2169-2173
37. Raut S., and Gaffney P.J. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies. Thromb Haemost 76 (1996) 56-64
38. Okumura N., Terasawa F., Hirota-Kawadobora M., Yamauchi K., Nakanishi K., Shiga S., et al. A novel variant fibrinogen, deletion of Bbeta111Ser in coiled-coil region, affecting fibrin lateral aggregation. Clin Chim Acta 365 (2006) 160-167
39. Sugo T., Nakamikawa C., Takano H., Mimuro J., Yamaguchi S., Mosesson M.W., et al. Fibrinogen Niigata with impaired fibrin assembly: an inherited dysfibrinogen with a Bbeta Asn-160 to Ser substitution associated with extra glycosylation at Bbeta Asn-158. Blood 94 (1999) 3806-3813
40. Lounes K.C., Lefkowitz J.B., Henschen-Edman A.H., Coates A.I., Hantgan R.R., and Lord S.T. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg->Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. Blood 98 (2001) 661-667
41. Yang Z., Mochalkin I., and Doolittle R.F. A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. PNAS 97 (2000) 14156-14161
42. Lugovskoy E.V., Kolesnikova I.N., Gritsenko P.G., Zolotareva E.N., Gaffney P., Nieuwenhuizen W., et al. A neoantigenic determinant in the D-dimer fragment of fibrin. Thromb Res 107 (2002) 151-156